Journal Articles

TRULANCE®

(plecanatide) 3 mg tablets

IBS-C

2022

Best practices for the management of chronic idiopathic constipation and irritable bowel syndrome with constipation: a roundtable discussion and review 

Brenner DM. American Journal of Gastroenterology [Supplement]. 2022.

Real-world treatment strategies to improve outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Brenner DM, et al. American Journal of Gastroenterology [Supplement]. 2022.

Burden of constipation: looking beyond bowel movements 

Harris LA, et al. American Journal of Gastroenterology [Supplement]. 2022.

Effective communication strategies and tools for improving treatment outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Kassebaum-Ladewski A, et al. American Journal of Gastroenterology [Supplement]. 2022

Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation 

Sayuk GS, et al. American Journal of Gastroenterology [Supplement]. 2022.

The effect of acid suppression therapy on the safety and efficacy of plecanatide: analysis of randomized phase III trials 

Moshiree B, et al. Clinical Therapeutics. 2022.

2021

Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders 

Sharma A, et al. Alimentary Pharmacology & Therapeutics. 2021.

Diagnosing constipation spectrum disorders in a primary care setting 

Heidelbaugh J, et al. Journal of Clinical Medicine. 2021.

2020

Evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in patients 65 years or older

Menees SB, et al. Clinical Therapeutics. 2020.

2019

Blunted evoked prouroguanylin endocrine secretion in chronic constipation

Waldman SA, et al. Clinical and Translational Gastroenterology. 2019.

Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation

Barish CF, et al. Current Medical Research and Opinion. 2019.

2018

Comment on meta analysis by Shah et al

Griffin PH. American Journal of Gastroenterology. 2018.

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

Waldman SA, et al. Gut. 2018.

Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire

Quigley EMM, et al. Advances in Therapy. 2018.

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

Brenner DM, et al. American Journal of Gastroenterology. 2018.

2017

Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog

Brancale A, et al. Pharmacology Research & Perspectives. 2017.

2013

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses

Shailubhai K, et al. Digestive Diseases and Sciences. 2013.

Access posters and abstracts
shared during scientific congresses.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)